Literature DB >> 18408765

CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor.

P Liu1, T P Kao, H Huang.   

Abstract

The forkhead box O (FOXO) transcription factor FOXO1 functions as a tumor suppressor by regulating expression of genes involved in apoptosis, cell cycle arrest and oxidative detoxification. Here, we demonstrate that cyclin-dependent kinase 1 (CDK1) specifically phosphorylates FOXO1 at serine 249 (S249) in vitro and in vivo. Coimmunoprecipitation assays demonstrate that both endogenous CDK1 and ectopically expressed CDK1 form a protein complex with FOXO1 in prostate cancer (PCa) cells. In vitro protein binding assays reveal that CDK1 interacts directly with FOXO1. Accordingly, overexpression of CDK1 inhibits the transcriptional activity of FOXO1 in PCa cells through S249 phosphorylation on FOXO1. Consistent with the roles of FOXO3a and FOXO4 (two other members of the FOXO family) in cell cycle regulation, forced expression of FOXO1 causes a delay in the transition from G2 to M phase. This effect is blocked completely by overexpression of CDK1 and cyclin B1. Ectopic expression of constitutively active CDK1 also inhibits FOXO1-induced apoptosis in PCa cells. Moreover, we demonstrate that the inhibitory effect of FOXO1 on Ras oncogene-induced colony formation in fibroblasts is diminished by overexpression of CDK1. Given that CDK1 and cyclin B1 are often overexpressed in human cancers including PCa, our findings suggest that aberrant activation of CDK1 may contribute to tumorigenesis by promoting cell proliferation and survival via phosphorylation and inhibition of FOXO1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408765     DOI: 10.1038/onc.2008.104

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  70 in total

1.  Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.

Authors:  Huarui Lu; Ping Liu; Yunqian Pan; Haojie Huang
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

Review 2.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

3.  Role of dephosphorylation of FOXO1 on apoptosis induced by wortmannin for non-Hodgkin's lymphoma cells.

Authors:  Zhan Qiong; Huang Ruofan; Liang Xiaohua; Zhou Xinli; Jiang Jingwei; Chu Zhaohui
Journal:  Mol Biol Rep       Date:  2009-09-11       Impact factor: 2.316

4.  The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation.

Authors:  Chengfu Yuan; Lei Wang; Liang Zhou; Zheng Fu
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

5.  Using a Multi-Stage hESC Model to Characterize BDE-47 Toxicity during Neurogenesis.

Authors:  Hao Chen; Helia Seifikar; Nicholas Larocque; Yvonne Kim; Ibrahim Khatib; Charles J Fernandez; Nicomedes Abello; Joshua F Robinson
Journal:  Toxicol Sci       Date:  2019-06-07       Impact factor: 4.849

6.  Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1.

Authors:  Peng Xia; Jingrui Chen; Yuening Liu; Maya Fletcher; Brian C Jensen; Zhaokang Cheng
Journal:  J Biol Chem       Date:  2020-02-19       Impact factor: 5.157

7.  The identification of key genes in nasopharyngeal carcinoma by bioinformatics analysis of high-throughput data.

Authors:  Yanshan Ge; Zhengxi He; Yanqi Xiang; Dawei Wang; Yuping Yang; Jian Qiu; Yanhong Zhou
Journal:  Mol Biol Rep       Date:  2019-03-04       Impact factor: 2.316

8.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Authors:  Laura R Bohrer; Ping Liu; Jian Zhong; Yunqian Pan; James Angstman; Lucas J Brand; Scott M Dehm; Haojie Huang
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

Review 9.  A fork in the path: Developing therapeutic inroads with FoxO proteins.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Jul-Aug       Impact factor: 6.543

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.